PeptiDream (4587) Fundamentals 2026 — Revenue Analysis | SniperIQ
PeptiDream (4587) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥122.6B, trading at ¥954.40 on the JPX. This SniperIQ fundamentals page covers PeptiDream's valuation, profitability (net margin -18.7%), revenue (¥18.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PeptiDream's market cap?
PeptiDream (4587) has a market capitalization of approximately ¥122.6B, trading at ¥954.40 on the JPX. Market cap moves with the live share price.
What is PeptiDream's P/E ratio?
PeptiDream's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PeptiDream?
PeptiDream runs a net profit margin of -18.7%, a gross margin of 42.4%, and an operating margin of -24.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PeptiDream generate?
PeptiDream reported revenue of ¥18.5B for fiscal year 2025, with net income of -¥3.7B and earnings per share (EPS) of -28.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PeptiDream pay a dividend?
PeptiDream does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PeptiDream financially healthy?
PeptiDream carries a debt-to-equity ratio of 0.33x and a current ratio of 4.06x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PeptiDream a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PeptiDream (4587) the key facts are: market cap ¥122.6B, revenue ¥18.5B, 52-week range 916-1818.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PeptiDream's full fundamentals live
Get PeptiDream's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.